$61.3 Million is the total value of OUP Management Co., LLC's 14 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVTE | Aerovate Therapeutics Inc. | $17,690,227 | +76.7% | 603,762 | 0.0% | 28.88% | +85.3% | |
| CNTA | Centessa Pharmaceuticals plcsponsored ads | $9,106,607 | -22.9% | 2,937,615 | 0.0% | 14.87% | -19.2% | |
| PMVP | PMV Pharmaceuticals, Inc. | $8,606,318 | -26.9% | 989,232 | 0.0% | 14.05% | -23.4% | |
| Sell | DICE Therapeutics Inc. | $8,372,395 | -23.1% | 268,346 | -50.0% | 13.67% | -19.4% | |
| ionQ, Inc. | $4,062,710 | -31.9% | 1,177,597 | 0.0% | 6.63% | -28.7% | ||
| CYT | Sell | Cyteir Therapeutics, Inc. | $4,058,294 | -14.4% | 2,459,572 | -0.4% | 6.63% | -10.3% |
| VOR | Vor Biopharma Inc. | $2,491,848 | +67.1% | 374,714 | 0.0% | 4.07% | +75.2% | |
| New | Prime Medicine, Inc. | $2,252,918 | – | 121,255 | +100.0% | 3.68% | – | |
| GRPH | Graphite Bio | $1,348,943 | +4.7% | 406,308 | 0.0% | 2.20% | +9.8% | |
| DTIL | Precision BioSciences, Inc. | $1,337,456 | -8.5% | 1,123,913 | 0.0% | 2.18% | -4.0% | |
| SELB | Selecta Biosciences, Inc. | $974,674 | -31.1% | 862,543 | 0.0% | 1.59% | -27.8% | |
| eFFECTOR Therapeutics, Inc. | $438,588 | -25.3% | 1,025,697 | 0.0% | 0.72% | -21.7% | ||
| SPRO | Spero Therapeutics, Inc. | $430,891 | -13.5% | 249,070 | 0.0% | 0.70% | -9.3% | |
| FIXX | Homology Medicines, Inc. | $80,640 | -21.7% | 64,000 | 0.0% | 0.13% | -17.5% | |
| LABP | Exit | Landos Biopharma, Inc. | $0 | – | -1,237,667 | -100.0% | -1.25% | – |
| Exit | Evolv Technologies Holdings, Inc. | $0 | – | -652,475 | -100.0% | -2.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-02
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Centessa Pharmaceuticals plc | 8 | Q3 2023 | 42.7% |
| Aerovate Therapeutics Inc. | 8 | Q3 2023 | 28.9% |
| PMV Pharmaceuticals, Inc. | 8 | Q3 2023 | 19.4% |
| Cyteir Therapeutics, Inc. | 8 | Q3 2023 | 15.7% |
| Vor Biopharma Inc. | 8 | Q3 2023 | 4.1% |
| Precision BioSciences, Inc. | 8 | Q3 2023 | 3.7% |
| Graphite Bio | 8 | Q3 2023 | 2.3% |
| eFFECTOR Therapeutics, Inc. | 8 | Q3 2023 | 3.8% |
| Selecta Biosciences, Inc. | 8 | Q3 2023 | 2.4% |
| Spero Therapeutics, Inc. | 8 | Q3 2023 | 1.8% |
View OUP Management Co., LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-07 |
| 13F-HR | 2023-04-24 |
| 13F-HR | 2023-02-02 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-19 |
| 13F-HR | 2022-05-04 |
| 13F-HR | 2022-02-03 |
View OUP Management Co., LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.